JMP Securities Reaffirms “Outperform” Rating for Arbutus Biopharma Corporation (ABUS)
Arbutus Biopharma Corporation (NASDAQ:ABUS)‘s stock had its “outperform” rating restated by stock analysts at JMP Securities in a report issued on Wednesday. They currently have a $13.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $12.00. JMP Securities’ price objective would indicate a potential upside of 72.19% from the stock’s previous close.
A number of other brokerages have also recently issued reports on ABUS. Zacks Investment Research cut Arbutus Biopharma Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma Corporation in a research report on Monday, August 7th. Wedbush restated an “outperform” rating and issued a $9.00 price target on shares of Arbutus Biopharma Corporation in a report on Wednesday, September 20th. Finally, ValuEngine upgraded shares of Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a report on Thursday, September 21st. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $12.65.
Arbutus Biopharma Corporation (ABUS) traded down 1.656% during trading on Wednesday, reaching $7.425. The company’s stock had a trading volume of 255,567 shares. The company’s market capitalization is $408.57 million. The company’s 50-day moving average is $4.98 and its 200-day moving average is $3.87. Arbutus Biopharma Corporation has a 1-year low of $2.35 and a 1-year high of $8.25.
In other Arbutus Biopharma Corporation news, insider Michael J. Sofia sold 30,000 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $3.70, for a total transaction of $111,000.00. Following the transaction, the insider now owns 1,563,403 shares in the company, valued at $5,784,591.10. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 10.00% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Montreal Can grew its stake in shares of Arbutus Biopharma Corporation by 1.9% in the second quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock valued at $3,147,000 after buying an additional 16,535 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Arbutus Biopharma Corporation during the 2nd quarter valued at about $478,000. Renaissance Technologies LLC raised its holdings in shares of Arbutus Biopharma Corporation by 785.1% during the 1st quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 110,499 shares during the period. OxFORD Asset Management LLP raised its holdings in shares of Arbutus Biopharma Corporation by 89.9% during the 2nd quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 39,436 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Arbutus Biopharma Corporation by 2.7% during the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,035 shares during the period. 67.04% of the stock is owned by institutional investors.
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.